ReviewHuman vaccines & immunotherapeutics2022
Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: Case report and scope review.
Review in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.BMC neurology · 2023Pooled it
- Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies.BMC neurology · 2023Pooled it
- Guillain Barré syndrome after combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine: A rare pediatric case report and review of literature.Human vaccines & immunotherapeutics · 2023Pooled it
- Miller Fisher syndrome: a case report and review of the literature.Journal of medical case reports · 2026Review
- Frequency of anti-GQ1b IgG antibody in Miller Fisher syndrome: a Chinese single center study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Sequential administration of efgartigimod shortened the course of Guillain-Barré syndrome: a case series.Therapeutic advances in neurological disorders · 2025Article
- The Ambivalence of Post COVID-19 Vaccination Responses in Humans.Biomolecules · 2024Review
- [Miller-Fisher/Guillain-Barré overlap syndrome following COVID-19 vaccination].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- Reply to the letter to the editor titled "Guillain-Barre / Miller-Fisher overlap syndrome or acute, motor and sensory, axonal neuropathy with cranial nerve involvement?"Human vaccines & immunotherapeutics · 2023Article
- Miller Fisher syndrome: an updated narrative review.Frontiers in neurology · 2023Review
- Guillain-Barre/Miller-Fisher overlap syndrome or acute, motor and sensory, axonal neuropathy with cranial nerve involvement?Human vaccines & immunotherapeutics · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miller-Fisher syndrome (MFS) is a rare variant of Guillain-Barré syndrome (GBS) manifesting as the triad of ataxia, areflexia, and ophthalmoplegia. With the extensive 2019 coronavirus disease (COVID-19) immunization program, cases of GBS or MFS following vaccination are increasingly being reported. A 64-y-old Chinese man presented with new-onset paresthesia of the extremities, bilateral abduction limitation, right facial palsy, areflexia of bilateral lower limbs, and left-dominant limb ataxia 12 d after the second dose of inactivated vaccine against COVID-19. Cerebrospinal fluid analysis indicated albumin-cytological dissociation and was positive for anti-GQ1b IgG and anti-GT1b IgG. Nerve conduction studies of limbs showed evidence of axonal neuropathy with reduced sensory amplitudes. Based on the clinical presentations, temporal progression of symptoms, and laboratory findings, the diagnosis of MFS-GBS overlap syndrome was made. The patient was treated with intravenous immunoglobulin and acupuncture and made a complete recovery 54 d after the onset of his initial neurological signs. To the best of our knowledge, we report the first case of MFS-GBS overlap syndrome following the inactivated COVID-19 vaccination. However, a coincidental relationship with this inactivated vaccine cannot be excluded. Although the benefits of COVID-19 vaccination largely outweigh its risk and the prognosis of MFS is generally favorable, a close surveillance of neurological complications post-COVID-19 vaccination is always necessary, considering its potentially disabling and lethal effects on vaccinated populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.